|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
ES2111065T5
(es)
|
1991-04-16 |
2005-06-16 |
Nippon Shinyaku Company, Limited |
Procedimiento para producir una dispersion solida.
|
|
CZ282760B6
(cs)
|
1991-11-22 |
1997-09-17 |
Procter And Gamble Pharmaceuticals, Inc. |
Risedronátové prostředky se zpožděným uvolňováním
|
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
WO1994008568A1
(fr)
|
1992-10-16 |
1994-04-28 |
Nippon Shinyaku Co., Ltd. |
Procede pour fabriquer des matrices de cire
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
KR19990014865A
(ko)
|
1995-05-17 |
1999-02-25 |
피터 이. 브래이브맨 |
소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
|
|
JP3498456B2
(ja)
|
1995-12-11 |
2004-02-16 |
Ｊｓｒ株式会社 |
液晶表示素子
|
|
AU3951899A
(en)
|
1998-06-19 |
2000-01-05 |
Pfizer Products Inc. |
Pyrrolo(2,3-d)pyrimidine compounds
|
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
|
MXPA02001498A
(es)
|
1999-08-12 |
2003-07-21 |
Pharmacia & Italia S P A |
Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
|
|
DZ3398A1
(fr)
|
2000-08-31 |
2002-03-07 |
Pfizer Prod Inc |
Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
|
|
US20050209297A1
(en)
|
2000-08-31 |
2005-09-22 |
Pfizer Inc |
Pyrazole derivatives
|
|
AU2002215053A1
(en)
|
2000-11-27 |
2002-06-24 |
Pharmacia Italia S.P.A. |
Phenylacetamido- pyrazole derivatives and their use as antitumor agents
|
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
|
WO2002083648A1
(fr)
|
2001-04-16 |
2002-10-24 |
Eisai Co., Ltd. |
Nouveau compose a base de 1h-indazole
|
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
IL161576A0
(en)
|
2001-10-26 |
2004-09-27 |
Aventis Pharma Inc |
Benzimidazoles and analogues and their use as protein kinases inhibitors
|
|
FR2831536A1
(fr)
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
|
DE10219294A1
(de)
|
2002-04-25 |
2003-11-13 |
Schering Ag |
Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
|
|
US20050282814A1
(en)
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
MXPA05003477A
(es)
|
2002-10-03 |
2005-07-22 |
Targegen Inc |
Agentes vasculo-estaticos y metodos de uso de los mismos.
|
|
WO2004089416A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
|
|
WO2005000197A2
(en)
|
2003-04-11 |
2005-01-06 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
|
DE602004027171D1
(de)
|
2003-04-11 |
2010-06-24 |
High Point Pharmaceuticals Llc |
Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
|
|
WO2004089415A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
|
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
WO2005030206A1
(en)
|
2003-09-24 |
2005-04-07 |
Imclone Systems Incorporated |
Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
|
|
WO2005042495A1
(en)
|
2003-10-21 |
2005-05-12 |
Imclone Systems Incorporated |
(benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
|
|
EP1682143A2
(en)
|
2003-10-28 |
2006-07-26 |
Pharmacia Corporation |
Combinations comprising an hsp90 inhibitor and a phophodiesterase inhibitor for treating or preventing neoplasia
|
|
ES2364340T3
(es)
|
2004-03-30 |
2011-08-31 |
Vertex Pharmaceuticals Incorporated |
Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
|
|
US7514448B2
(en)
|
2004-04-02 |
2009-04-07 |
Vertex Pharmaceuticals Incorporated |
Azaindoles useful as inhibitors of rock and other protein kinases
|
|
UY28931A1
(es)
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
|
US7691888B2
(en)
|
2004-10-07 |
2010-04-06 |
Boehringer Ingelheim International Gmbh |
Thiazolyl-dihydro-indazole
|
|
DE102004048877A1
(de)
|
2004-10-07 |
2006-04-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
PI3-Kinasen
|
|
AU2005309566A1
(en)
|
2004-11-22 |
2006-06-01 |
Vertex Pharmaceuticals Incorporated |
Bicyclic inhibitors or Rho kinase
|
|
FR2878849B1
(fr)
|
2004-12-06 |
2008-09-12 |
Aventis Pharma Sa |
Indoles substitues, compositions les contenant, procede de fabrication et utilisation
|
|
DOP2006000051A
(es)
|
2005-02-24 |
2006-08-31 |
Lilly Co Eli |
Inhibidores de vegf-r2 y métodos
|
|
GB0507575D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
JP2008540395A
(ja)
|
2005-05-03 |
2008-11-20 |
ファイザー・インク |
アミドレソルシノール化合物
|
|
FR2885904B1
(fr)
|
2005-05-19 |
2007-07-06 |
Aventis Pharma Sa |
Nouveaux derives du fluorene, compositions les contenant et utilisation
|
|
ATE485269T1
(de)
|
2005-06-27 |
2010-11-15 |
Bristol Myers Squibb Co |
C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
|
|
US7345178B2
(en)
|
2005-08-04 |
2008-03-18 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
DE102005037499A1
(de)
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
|
EP1955077B1
(en)
|
2005-12-02 |
2012-06-13 |
Sirtris Pharmaceuticals, Inc. |
Mass spectrometry assays for acetyltransferase/deacetylase activity
|
|
BRPI0619146A2
(pt)
|
2005-12-02 |
2011-09-13 |
Bayer Pharmaceuticals Corp |
derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
|
|
BRPI0707719A2
(pt)
|
2006-02-10 |
2011-05-10 |
Summit Corp Plc |
uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
|
|
US8008481B2
(en)
|
2006-03-31 |
2011-08-30 |
Ericsson Anna M |
Indazole compounds
|
|
WO2008075196A1
(en)
|
2006-12-15 |
2008-06-26 |
Pfizer Products Inc. |
Benzimidazole derivatives
|
|
AU2008285289A1
(en)
|
2007-08-03 |
2009-02-12 |
Biomarin Iga Limited |
Drug combinations for the treatment of Duchenne muscular dystrophy
|
|
RU2364597C1
(ru)
|
2007-12-14 |
2009-08-20 |
Андрей Александрович Иващенко |
ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
|
|
AU2008345225A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
US20100168084A1
(en)
|
2008-05-08 |
2010-07-01 |
Huber L Julie |
Therapeutic compounds and related methods of use
|
|
WO2010011762A1
(en)
|
2008-07-23 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyridine kinase inhibitors
|
|
WO2010129620A1
(en)
|
2009-05-05 |
2010-11-11 |
Alla Chem, Llc |
Imidazo [ 1, 2 -a] pyridin-2 -yl-phenyl derivatives to be used in cancer treatment
|
|
WO2011026579A1
(en)
|
2009-09-04 |
2011-03-10 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
|
GB201009853D0
(en)
|
2010-06-11 |
2010-07-21 |
Chroma Therapeutics Ltd |
HSP90 inhibitors
|
|
EP2694060A4
(en)
|
2011-04-01 |
2014-09-10 |
Univ Utah Res Found |
SUBSTITUTED 3- (1H-BENZO- {D} -IMIDAZOL-2-YL-) 1H-INDAZOL ANALOGUE AS PDK1 KINASE INHIBITOR
|
|
JP2014166961A
(ja)
|
2011-06-20 |
2014-09-11 |
Dainippon Sumitomo Pharma Co Ltd |
新規インダゾール誘導体
|
|
CN102266341A
(zh)
|
2011-06-20 |
2011-12-07 |
广州市第十二人民医院 |
嗓唑并嘧啶类化合物在制备治疗肺癌药物中的应用
|
|
JP2016506943A
(ja)
|
2013-01-30 |
2016-03-07 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
|
|
KR20140125117A
(ko)
|
2013-04-18 |
2014-10-28 |
한국화학연구원 |
카르바닐리드 유도체를 유효성분으로 포함하는 이상증식혈관 질환의 예방 또는 치료용 조성물
|
|
WO2015000959A1
(en)
|
2013-07-03 |
2015-01-08 |
Norwegian University Of Science And Technology (Ntnu) |
4-amino-6-aryl[2,3-d]pyrimidines for the inhibition of egfr tyrosine kinase
|
|
GB201316824D0
(en)
|
2013-09-23 |
2013-11-06 |
R & D Vernalis Ltd |
New Chemical Entities
|
|
JP2015183128A
(ja)
|
2014-03-25 |
2015-10-22 |
東洋インキＳｃホールディングス株式会社 |
波長変換性樹脂組成物及び太陽電池封止材
|
|
EP2924039A1
(en)
|
2014-03-27 |
2015-09-30 |
Universität Zürich |
2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates
|
|
CA2949793C
(en)
|
2014-06-19 |
2024-02-27 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
|
GB201417561D0
(en)
|
2014-10-03 |
2014-11-19 |
Redx Pharma Ltd |
Compounds
|
|
TWI698436B
(zh)
|
2014-12-30 |
2020-07-11 |
美商佛瑪治療公司 |
作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
|
|
TW201643143A
(zh)
|
2015-03-13 |
2016-12-16 |
國立大學法人北海道大學 |
抑制氧化壓迫引發的神經細胞死亡之化合物
|
|
WO2016197078A1
(en)
|
2015-06-05 |
2016-12-08 |
Syros Pharmaceuticals, Inc. |
Compounds for the modulation of myc activity
|
|
WO2016202758A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
US10093668B2
(en)
|
2015-10-28 |
2018-10-09 |
Northwestern University |
Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)
|
|
US10851082B2
(en)
|
2015-10-28 |
2020-12-01 |
Northwestern University |
Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
|
|
CN107176951A
(zh)
|
2016-03-11 |
2017-09-19 |
恩瑞生物医药科技（上海）有限公司 |
一种脲类化合物、其制备方法及其医药用途
|
|
US10752639B2
(en)
|
2016-03-16 |
2020-08-25 |
Kura Oncology, Inc. |
Bridged bicyclic inhibitors of menin-MLL and methods of use
|
|
WO2017161028A1
(en)
|
2016-03-16 |
2017-09-21 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-mll and methods of use
|
|
US10630430B2
(en)
|
2016-03-18 |
2020-04-21 |
Kyocera Corporation |
System and method for dual-coding for dual-hops channels
|
|
CN109415337B
(zh)
|
2016-05-02 |
2022-01-18 |
密执安大学评议会 |
作为多发性内分泌腺瘤蛋白抑制剂的哌啶
|
|
CN105997965B
(zh)
|
2016-05-25 |
2018-05-08 |
山东大学 |
小分子化合物作为佐剂在制备抗真菌药物中的应用
|
|
ES2831084T3
(es)
|
2016-06-10 |
2021-06-07 |
Vitae Pharmaceuticals Inc |
Inhibidores de la interacción menina-MLL
|
|
WO2018106818A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
US11452717B2
(en)
|
2017-01-10 |
2022-09-27 |
Sanford Burnham Prebys Medical Discovery Institute |
Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
|
|
US11247970B2
(en)
|
2017-03-22 |
2022-02-15 |
Dana-Farber Cancer Institute, Inc. |
Selective inhibition of gluconeogenic activity
|
|
EP3600313A4
(en)
|
2017-03-31 |
2020-09-23 |
The Regents of The University of Michigan |
PIPERIDINES AS COVALENT MENINE INHIBITORS
|
|
EP3774797B1
(en)
|
2018-04-05 |
2025-11-19 |
Merck Patent GmbH |
Heteroaryl compounds as type ii irak inhibitors and uses hereof
|
|
CN108727295B
(zh)
|
2018-06-21 |
2022-04-01 |
济南大学 |
一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
|
|
WO2020142557A1
(en)
|
2018-12-31 |
2020-07-09 |
Biomea Fusion, Llc |
Irreversible inhibitors of menin-mll interaction
|
|
TW202043205A
(zh)
|
2018-12-31 |
2020-12-01 |
美商拜歐米富士恩有限公司 |
Menin-mll相互作用之抑制劑
|
|
CA3294689A1
(en)
|
2019-06-26 |
2026-03-02 |
Nurix Therapeutics, Inc. |
Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
|
|
EP4263542A1
(en)
|
2020-12-16 |
2023-10-25 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
|
JP7891524B2
(ja)
|
2021-08-11 |
2026-07-16 |
バイオメア フュージョン，インコーポレイテッド |
真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤
|
|
MX2024002189A
(es)
|
2021-08-20 |
2024-06-11 |
Biomea Fusion Inc |
Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
|